Medicinal chemistry of target family-directed masterkeys.

The majority of pharmaceutically relevant drug targets cluster into densely populated target families, thus offering a novel approach that complements the currently favoured screening paradigm in medicinal chemistry. This approach uses a privileged structure concept whereby molecular masterkeys are developed that account for a target family wide structural or functional commonality. Numerous lead compounds, based on multipurpose privileged structures, can be generated that address a variety of targets from a gene family of interest, irrespective of therapeutic area. Several different interpretations of the privileged structure concept will be highlighted, with a strong emphasis on the most stringent application: the optimization of a molecular masterkey for a distinct target family of interest.

[1]  F. Collins,et al.  New goals for the U.S. Human Genome Project: 1998-2003. , 1998, Science.

[2]  J. Drews.  Genomic sciences and the medicine of tomorrow , 1996, Nature Biotechnology.

[3]  T. Petcher,et al.  An opioid benzodiazepine , 1982, Nature.

[4]  P. Hajduk,et al.  Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.

[5]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[6]  R. Dolle.  Comprehensive survey of combinatorial library synthesis: 2000. , 2001, Journal of combinatorial chemistry.

[7]  R. Chang,et al.  Tifluadom, a κ-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist , 1986, Neuroscience Letters.

[8]  Barbara M. Bolten,et al.  Trends in development cycles , 2002, Nature Reviews Drug Discovery.

[9]  P. Jones,et al.  Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease. , 2002, Organic letters.

[10]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[11]  G. Foster,et al.  Isolation of translactone-containing triterpenes with thrombin inhibitory activities from the leaves of Lantana camara. , 1998, Journal of natural products.

[12]  J. Drews,et al.  Drug Development: The role of innovation in drug development , 1997, Nature Biotechnology.

[13]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[14]  R. Dolle.  Comprehensive survey of combinatorial library synthesis: 2001. , 2002, Journal of combinatorial chemistry.

[15]  Wolfgang Guba,et al.  Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.

[16]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.

[17]  H. Miller.  As biotech turns 20... , 2002, Nature Reviews Drug Discovery.

[18]  G. Hart,et al.  Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 1. The alpha-methyl-trans-lactam template. , 2000, Journal of medicinal chemistry.

[19]  Drews.  Drug discovery today - and tomorrow. , 2000, Drug discovery today.

[20]  Martin R. Johnson,et al.  Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151). , 2002, Journal of medicinal chemistry.

[21]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[22]  J. Drews.  Stategic trends in the drug industry. , 2003, Drug discovery today.

[23]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[24]  Peter Ertl,et al.  Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality. , 2002, Journal of medicinal chemistry.

[25]  Brian K Shoichet,et al.  Kinase inhibitors: not just for kinases anymore. , 2003, Journal of medicinal chemistry.

[26]  C. Wharton,et al.  Novel natural product 5,5-trans-lactone inhibitors of human alpha-thrombin: mechanism of action and structural studies. , 1998, Biochemistry.

[27]  D. Szymkowski.  Too many targets, not enough target validation. , 2001, Drug discovery today.

[28]  G. Hardy,et al.  The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate. , 2001, Bioorganic & medicinal chemistry letters.

[29]  J. Montana,et al.  5,5-trans lactone-containing inhibitors of serine proteases: identification of a novel, acylating thrombin inhibitor. , 1998, Bioorganic & medicinal chemistry letters.

[30]  Arthur A. Patchett,et al.  Chapter 26. Privileged structures — An update , 2000 .

[31]  Jürgen Drews,et al.  Innovation Deficit in the Pharmaceutical Industry , 1996 .

[32]  K. Chapman,et al.  Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. , 2002, Bioorganic & medicinal chemistry letters.

[33]  Günther Wess,et al.  Medicinal Chemistry: Challenges and Opportunities. , 2001, Angewandte Chemie.

[34]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[35]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[36]  J. Drews.  In Quest of Tomorrow's Medicines , 1999 .

[37]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[38]  N. Ramsden,et al.  Thrombin inhibitors based on [5,5] trans-fused indane lactams. , 1999, Bioorganic & medicinal chemistry letters.